Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Eloralintide
Eloralintide and Tirzepatide · 4 trials · 2 indications
PK: AUC of Eloralintide and Tirzepatide
PK: Cmax of Eloralintide and Tirzepatide
PK: AUC of Eloralintide and Tirzepatide
PK: Cmax of Eloralintide and Tirzepatide
PK: AUC of Eloralintide
PK: Cmax of Eloralintide
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Eloralintide Dose 1 | EXPERIMENTAL | Participants will receive eloralintide subcutaneously (SC) |
| Eloralintide Dose 2 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Eloralintide Dose 3 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Eloralintide Dose 4 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Eloralintide | EXPERIMENTAL | Eloralintide administered subcutaneously (SC) |
| Eloralintide and Tirzepatide-Cohorts A-D | EXPERIMENTAL | Eloralintide and Tirzepatide administered subcutaneously (SC) |
| Eloralintide-Cohorts E and F | EXPERIMENTAL | Eloralintide administered SC |
| Name | Type | Description |
|---|---|---|
| Eloralintide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| Eloralintide and Tirzepatide | DRUG | Administered SC |
Inclusion Criteria: * Are on stable incretin therapy at screening * With persistent obesity or overweight defined as: * ≥30 kg/m2 OR * ≥27 kg/m2 with at least one existing obesity related complication at screening: * hypertension * dyslipidemia * obstructive sleep apnea * card...
Eloralintide is an investigational small molecule being studied for obesity, overweight, osteoarthritis knee pain, and obstructive sleep apnea in people with obesity or overweight. It is also being evaluated in healthy volunteers. The drug is in clinical development by Eli Lilly and Company and is not yet approved.
Eloralintide is a peptide-based small molecule, classified under the -tide (peptide) target class. Its specific molecular target is not disclosed in available clinical trial information. The drug is being studied for its effects on body weight and related conditions such as osteoarthritis and sleep apnea.
Eloralintide is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The company is conducting clinical trials of Eloralintide across multiple countries, including the United States, China, and several European and Asian nations.
Eloralintide is in Phase 1 and Phase 3 clinical trials. Phase 1 studies are evaluating safety and tolerability in healthy participants and in Chinese participants with obesity or overweight. Phase 3 trials are recruiting participants with osteoarthritis knee pain or obstructive sleep apnea who also have obesity or overweight.
Eloralintide has four registered clinical trials. NCT06916091 is a completed Phase 1 study in Chinese participants with obesity or overweight. NCT07353931 is a recruiting Phase 3 trial for osteoarthritis knee pain. NCT07369011 is a recruiting Phase 3 trial for obstructive sleep apnea. NCT07701083 is a recruiting Phase 1 study in healthy participants.
Yes, Eloralintide is also known as LY3841136. Clinical trial records use both names interchangeably, with LY3841136 appearing in study titles and Eloralintide as the drug name. Patients and researchers searching for either name will find the same investigational drug being developed by Eli Lilly.